References

1. 1.
   RAJBHANDARI J，FERNANDEZ C J，AGARWAL M，et al.Diabetic heart disease：A clinical update［J］.World J Diabetes，2021，12（4）：383-406.
2. 2.
   RULLBER S，DULGUSH J，YUCEOGL Y Z，et al.New type of cardiomyopathy associated with diabetic glomerulosclerosis［J］.Am J Cardiol，1972，30：595-602.
3. 3.
   PAOLILLO S，MARSICO F，PRASTARO M，et al.Diabetic cardiomyopathy：definition，diagnosis，and therapeutic implications［J］.Heart Fail Clin，2019.
4. 4.
   ELLIOTT P，ANDERSSON B，ARBUSTINI E，et al.Classification of the cardiomyopathies：A position statement from the European society of cardiology working group on myocardial and pericardial diseases［J］.Eur Heart J，2008，29（2）：270-276.
5. 5.
   YOU L Z，PAN H E，DAI Q Q，et al.Pathogenesis of diabetic heart disease in traditional Chinese medicine［J］.J Tradit Chin Med，2021，62（12）：1013-1019.
6. 6.
   LYU C Q，NIU W L，LIU X W，et al.Textual research on Shengmaisan from ancient literature and its modern clinical application［J］.Chin J Exp Tradit Med Form，2024，doi：.
7. 7.
   ZHOU H Y.Study on the therapeutic basis of traditional Chinese medicinal preparation Shengmai injections［D］.Changchun：Jilin University，2011.
8. 8.
   LI F，CHENG T F，DONG X，et al.Global analysis of chemical constituents in Shengmai injection using high performance liquid chromatography coupled with tandem mass spectrometry［J］.J Pharm Biomed Anal，2016，117：61-72.
9. 9.
   WANG H，TANG L，HU S，et al.Chemical profiling of Shengmai injection，tissue distribution and pharmacokinetic characteristics of ginsenosides after intravenous dosing Shengmai injection in rats with cerebral ischemia［J］.J Ethnopharmacol，2024，319（Pt 1）：117119.
10. 10.
    LI W Z，YANG J Y，ZHAO F，et al.Fingerprint of Shenmai injection based on H-NMR technique［J］.China J Chin Mater Med，2022，47（3）：581-586.
11. 11.
    AO L，CHEN Z，YIN J，et al.Chinese herbal medicine and active ingredients for diabetic cardiomyopathy：Molecular mechanisms regulating endoplasmic reticulum stress［J］.Front Pharmacol，2023，14：1290023.
12. 12.
    BAI L，GAO J，WEI F，et al.Therapeutic potential of ginsenosides as an adjuvant treatment for diabetes［J］.Front Pharmacol，2018，9：423.
13. 13.
    ZHAO L L，ZHANG Y，XUE H，et al.Study on the protective effect and mechanism of Ophioside D on hypoxia and reoxygenation injury of rat cardiomyocytes［J］.Chin Circ J，2022，37（2）：178-184.
14. 14.
    TANG X L，LIN Y，WANG Y G，et al.Effect of aspartoside D on fatty acid metabolizing enzymes in cardiomyocytes［J］.Chin J Tradit Chin Med，2021，46（14）：3672-3677.
15. 15.
    WANG Z，SHEN S C.Determination of contents of seven lignansin Shengmaiyin by UPLC-MS［J］.Chin J Hospit Pharm，2017，37（16）：1590-1593.
16. 16.
    YANG M，JIANGXC，WANG L，et al.Schisandrin protects against norepinephrine-induced myocardialhypertrophicinjury byinhibiting the JAK2/STAT3 signaling pathway［J］.Evid Based Complement Alternat Med，2021，2021：8129512.
17. 17.
    WANG Q，LIU Y，ZHENG X W，et al.Study on homoisoflavones in Shengmai injection［J］.Chin Pharm J，2012，47（19）：1539-1542.
18. 18.
    JUBAIDI F F，ZAINALABIDIN S，TAIB I S，et al.The potential role of flavonoids in ameliorating diabetic cardiomyopathy via alleviation of cardiac oxidative stress，inflammation and apoptosis［J］.Int J Mol Sci，2021，22（10）：5094.
19. 19.
    XIA Y，LI Z M，ZHU D N，et al.A research on chemical dynamic changes and drug efficacy of SMS compound prescription chemical researches on sms prescription？［J］.China J Chin Mater Med，1998（4）：38-39，63.
20. 20.
    ZHU D N，LI Z M，YAN Y Q，et al.A research on chemical dynamic changes and drug efficacy of SMS compound prescription chemical researches on SMS prescription（Ⅱ）［J］.China J Chin Mater Med，1998（5）：35-37，63-64.
21. 21.
    ZHU D N，YAN Y Q，LI Z M，et al.A research on chemical dynamic changes and drug efficacy of SMS compound prescription chemical researches on SMS prescription（Ⅲ）［J］.China J Chin Mater Med，1998（8）：35-37.
22. 22.
    YUE L，ZHU D N，YAN Y Q，et al.Relationship between components changes and efficacy of Shengmaisan （Ⅶ）．Chemical dynamic change of schisandrin in Shengmaisan［J］.China J Chin Mater Med，2006（12）：1010-1012.
23. 23.
    TANG J，DUAN W X，DENG P，et al.Cadmium disrupts mitochondrial distribution and activates excessive mitochondrialfission by elevating cytosolic calcium independent of MCU-mediated mitochondrial calcium uptake in its neurotoxicity［J］.Toxicology，2021，453：152726.
24. 24.
    XU W，WANG Z Y，LUO X C，et al.Effects of Shenmai injection on cardiac function of isolated toad［J］.J Mod Med Health，2011，27（16）：2403-2404.
25. 25.
    HEGYI B，PÖLÖNEN R P，HELLGREN K T，et al.Cardiomyocyte Na⁺ and Ca²⁺ mishandling drives vicious cycle involving CaMKII，ROS，and ryanodine receptors［J］.Basic Res Cardiol，2021，116：58.
26. 26.
    HUANG C，SUN M J，CUI H F，et al.The mechanism of ShengMaiSan reducing calcium leak and protecting myocardial contractile function in diabetic rats based on network pharmacology［J］.Acta Pharm Sinica，2022，57（10）：3115-3123.
27. 27.
    ZHAI Q，SUN M J，CUI H F，et al.Regulatory effects of Shengmai powder on cardiac calcium transport proteins in diabetic rats［J］.J Bas Chin Med，2020，26（5）：601-604，665.
28. 28.
    MA S，LI X，DONG L，et al.Protective effect of Sheng-Mai Yin，a traditional Chinese preparation，against doxorubicin-induced cardiac toxicity in rats［J］.BMC Complement Altern Med，2016，16：61.
29. 29.
    SUN H X，HU B，LIN H J.Mechanism of polysaccharide of schisandra chinensis on inhibiting cardiac fibroblasts proliferation induced by angiotensin Ⅱ by extracellular regulated protein kinase 1/2 pathway［J］.J Beihua Univ：Nat Sci，2019，20（5）：640-644.
30. 30.
    SCHAFER S，VISWANATHAN S，WIDJAJA A A，et al.IL-11 is a crucial determinant of cardiovascular fibrosis［J］.Nature，2017，552（7683）：110-115.
31. 31.
    WANG J H，ZHAO L，PAN X，et al.Hypoxia-stimulated cardiac fibroblast production of IL-6 promotes myocardial fibrosis via the TGF-β₁ signaling pathway.Lab Invest，2016，96（8）：839-852.
32. 32.
    PENG D，FU M，WANG M，et al.Targeting TGF-β signal transduction for fibrosis and cancer therapy［J］.Mol Cancer，2022，21（1）：104.
33. 33.
    PaLOMER X，ROMÁN-AZCONA M S，PIZARRO-DELGADO J，et al.SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation［J］.Sig Transduct Target Ther，2020，51：14
34. 34.
    NI Q，WANG J，LI E Q，et al.Study on the protective effect of Shengmai san（see text） on the myocardium in the type 2 diabetic cardiomyopathy model rat［J］.J Tradit Chin Med，2011，31（3）：209-219.
35. 35.
    PAN J， CAO Z， FANG C， et al.Huangqi Shengmai Yin ameliorates myocardial fibrosis by activating sirtuin3 and inhibiting TGF-β/Smad pathway［J］.Front Pharmacol，2021，12：722530.
36. 36.
    WANG X L，FENG S T，WANG Z Z，et al.Role of mitophagy in mitochondrial quality control：Mechanisms and potential implications for neurodegenerative diseases［J］.Pharmacol Res，2021，165：105433.
37. 37.
    JIA Z W.The Mechanism of mitochondria quality control in mammals［J］.Chin J Cell Biol，2017，39（3）：373-380.
38. 38.
    UEMICHI K，SHIRAI T，HANAKITA H，et al.Effect of mechanistic/mammalian target of rapamycin complex 1 on mitochondrial dynamics during skeletal muscle hypertrophy［J］.Physiol Rep，2021，9（5）：e14789.
39. 39.
    CHEN Y，LIU Y，DORN G W.Mitochondrial fusion is essential for organelle function and cardiac homeostasis［J］.Circ Res，2011，109（12）：1327-1331.
40. 40.
    LYU M，CHANG X，LIN H Q，et al.Research on the effect of Huoxue Jiangtang drink on mitochondrial autophagy in diabetic cardiomyopathy［J］.World Chin Med，2020，15（24）：3777-3781.
41. 41.
    JI W，WEI S，HAO P，et al.Aldehyde dehydrogenase 2 Has cardioprotective effects on myocardial ischaemia/reperfusion injury via suppressing mitophagy［J］.Front Pharmacol，2016，7：101.
42. 42.
    WANG T，ZHU Q P，CAO B B，et al.Cadmium induces mitophagy via AMP ‐ activated protein kinases activation in a PINK1/Parkin‐dependent manner in PC12 cells［J］.Cell Prolif，2020，53（6）：e12817.
43. 43.
    YU W，GAO B，LI N，et al.Sirt3 deficiency exacerbates diabetic cardiac dysfunction：Role of Foxo3A-Parkin-mediated mitophagy［J］.Biochim Biophys Acta Mol Basis Dis，2017，1863（8）：1973-1983.
44. 44.
    YUAN Y H，YUAN R，MIAO Y，et al.Effect and mechanism of Huangqi Shengmai decoction in treatment of joint rat model of fatigue and myocardial injury［J］.China J Chin Mater Med，2022，47（19）：5292-5298.
45. 45.
    XU S W，GE J B，WENG J P，et al.Endothelial dysfunction and panvascular diseases［J］.J Univ Sci Technol China，2021，51（8）：577-585.
46. 46.
    HUGGINS C E，DOMENIGHETTI A A，RITCHIE M E，et al.Functional and metabolic remodelling in GLUT4-deficient hearts confers hyper-responsiveness to substrate intervention［J］.J Mol Cell Cardiol，2008，44（2）：270-280.
47. 47.
    XING X W，CHEN Z，ZHENG B D，et al.Improvement effects of Shengmai decoction on insulin resistance in diabetic rats［J］.Shanghai J Tradit Chin Med，2018，52（7）：80-84.
48. 48.
    SZKUDELSKI T，SZKUDELSKA K.The relevance of AMP-activated protein kinase in insulin-secreting β cells：A potential target for improving β cell function？［J］ J Physiol Biochem，2019，75（4）：423-432.
49. 49.
    LI Y，RUAN X，XU X，et al.Shengmai injection suppresses angiotensin Ⅱ-induced cardiomyocyte hypertrophy and apoptosis via activation of the AMPK signaling pathway through energy-dependent mechanisms［J］.Front Pharmacol，2019，10：1095.
50. 50.
    MAIER H J，SCHIPS T G，WIETELMANN A，et al.Cardiomyocyte-specific IκB kinase （IKK）/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure［J］.Proc Natl Acad Sci USA，2012，109（29）：11794-11799.
51. 51.
    DIVANOVIC S，TROMPOTTE A，ATABANI S F，et al.Negative regulation of Toll-like receptor 4 signaling by the Tolllike receptor homolog RP105［J］.Nat Immunol，2005，6（6）：1571-1578.
52. 52.
    TIMMERS L，SLUIJTER J P，HOEFER I E，et al.Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction［J］.Circ Res，2008，102（2）：257-264.
53. 53.
    HUANG W C，HUNG M C.Beyond NF-κB activation：nuclear functions of IκB kinase α［J］.J Biomed Sci，2013，20（1）：3.
54. 54.
    WANG X Y.Mechanism of Jiedutongluo drink on ragulation of the signal pathway of PPARγ-NF-κB-inflammatory cytokines on rat with diabetic cardiomyopathy［D］.Changchun：Changchun University of Chinese Medicine，2017.
55. 55.
    XING Q M，LU S，ZHOU Y H，et al.Effect of Shengmaisan on DCM rats and TLR-4 /NF-κB inflammatory signal pathway［J］.Chin J Exp Tradl Med Form，2018，24（2）：128-134.
56. 56.
    VERMOT A，PETIT-HÄRTLEIN I，SMITH S M E，et al.NADPH oxidases （NOX）：An overview from discovery，molecular mechanisms to physiology and pathology［J］.Antioxidants （Basel），2021，10（6）：890.
57. 57.
    LU Y，ZHU S，WANG X，et al.ShengMai-San attenuates cardiac remodeling in diabetic rats by inhibiting NOX-mediated oxidative stress［J］.Diabetes Metab Syndr Obes，2021，14：647-657.
58. 58.
    CHEANG W S，TIAN X Y，WONG W T，et al.The peroxisome proliferator-activated receptors in cardiovascular diseases：Experimental benefits and clinical challenges.Br J Pharmacol，2015，172（23）：5512-5122.
59. 59.
    LEE T I，KAO Y H，CHEN Y C，et al.Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy［J］.Diabetes Res Clin Pract，2013，100（3）：330-339.
60. 60.
    LIU J，YANG P，ZUO G，et al.Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress［J］.Lipid Health Dis，2018，17（153）：2-9.
61. 61.
    TEISSIER E，NOHARA A，CHINETTI G，et al.Peroxisome proliferatoractivated receptor alpha induces NADPH oxidase activity in macrophages，leading to the generation of LDL with PPAR-alpha activation properties［J］.Circ Res，2004，95（12）：1174-1182
62. 62.
    EMILY S，BILLY B，KNAUS U G.NAPDH oxidases in inflammatory bowel disease［J］.Methods Mol Biol，2019，1982：695-713.
63. 63.
    TIAN J，TANG W，XU M，et al.Shengmai San alleviates diabetic cardiomyopathy through improvement of mitochondrial lipid metabolic disorder［J］.Cell Physiol Biochem，2018，50（5）：1726-1739.
64. 64.
    HAJARNIS S，LAKHIA R，YHESKEL M，et al.MicroRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism［J］.Nat Commun，2017，8（1）：99-106
65. 65.
    LI Y Y.Study on the ameliorative effect and mechanism of Shengmai San on diabetic cardiomyopathy through oxidative stress pathway［D］.Jinan：Shandong University of Traditional Chinese Medicine，2022.
66. 66.
    ZHAI Q，SUN M J，CUI H F，et al.Protective effect of Shengmai powder on cardiac contractile function in diabetic rats［J］.China J Tradit Chin Med Pharm，2020，35（6）：2818-2823.
67. 67.
    LI Y Y，WANG W，WANG X，et al.Effects of Shengmai San on myocardial oxidative stress and miR-19a，PPARα，CD36 in type 2 diabetic rats［J］.China J Tradit Chin Med Pharmacy，2022，37（4）：2218-2222.
68. 68.
    SHEN L，LIU H M，HU X J，et al.Clinical observation of Dengzhan Shengmai capsules for type2 diabetes insulin resistance［J］.Chin Tradit Patent Med，2009，31（4）：499-501.
69. 69.
    WEI Y N，MO X M，WANG Q，et al.Protective effect of huangqi guizhi wuwutang combined with Shengmaiyin on cardiac function of diabetic cardiomyopathy［J］.Chin J Exp Tradit Med Form，2021，27（19）：104-109.
70. 70.
    Wang W.Dengshengmai capsule adjuvant treatment of diabetic cardiomyopathy with cardiac dysfunction patients curative effect （30 cases）［J］.Med Equip，2018，31（9）：103-104.